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Background: Recognition of the immunogenicity of standard cryopreserved allo-
grafts has led to the development of new decellularized allografts (CryoValve SG;
CryoLife, Inc, Kennesaw, Ga). This preliminary study examined the HLA antibody
response to these decellularized allografts and compared it with the response to
standard allograft material.
Methods: We prospectively measured the frequency of panel-reactive HLA class I
(HLA-A, HLA-B, and HLA-C) and class II (HLA-DR/DQ) alloantibodies in 14
children (age 8.5  7.9 years) receiving decellularized, cryopreserved allografts,
including 6 undergoing allograft patch insertion and 8 with a valved pulmonary
allograft. We compared them with 20 historical control subjects (age 1.7  2.4
years) undergoing implantation of standard cryopreserved allografts, 8 with valves
and 12 with allograft patch. All patients had panel-reactive antibody levels measured
before and at 1, 3, and 12 months after the operation. HLA class I and class II
panel-reactive antibody levels were determined with a sensitive flow cytometry
technique.
Results: We found panel-reactive antibody levels in decellularized allografts to
be elevated slightly from preoperative levels for both class I and class II
antibodies at 1, 3, and 12 months (P  .05). The panel-reactive antibody level
for both class I and class II antibodies were significantly lower for decellularized
allografts as compared to standard allografts. Functionally, the allografts were
similar with decellularized valved grafts showing a peak echo-determined sys-
tolic gradient of 13  15 mm Hg at 8  2.6 months postoperatively as compared
to a gradient of 24  18 mm Hg measured 12  6 months postoperatively in
standard allografts (P  .11).
Conclusions: Decellularized grafts elicited significantly lower levels of class I and
class II HLA antibody formation at 1, 3, and 12 months after implantation than did
standard cryopreserved allografts. Early hemodynamic function of decellularized
grafts was similar to that of standard cryopreserved allograft valves. Further expe-
rience is necessary to determine whether the reduced immunogenicity of decellu-
larized allografts will truly allow tissue ingrowth and improved long-term durability
in patients.
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Cryopreserved human allograft material isextensively used in cardiac surgery to re-construct a variety of congenital cardiacdefects and abnormalities. Because of thewidespread use of this cryopreserved allo-graft material, immunologic consequences
of allograft implantation have been investigated, as illus-
trated by reports from several groups of the activation of
anti-HLA antibodies.1-3 A new decellularized cryopre-
served allograft preparation has become available that the-
oretically will eliminate the immune response and, it is
hoped, allow host cell ingrowth and better durability.4 Only
limited experience and information with this new tissue has
been available to date, and only with older patients.5,6
Before the use of this human cryopreserved decellularized
tissue can become widespread, the immunologic conse-
quences and implications of this new tissue and valve prep-
aration must be evaluated in children. Infants and children
tend to have the greatest immunologic reaction to cryopre-
served allograft material,7 with a shorter period of freedom
from reintervention after valved allograft implantation than
is seen in adult patients.8,9 Thus infants and children may
have the most to gain from the development of newer
technologies that abolish immunogenicity and prolong du-
rability.
This preliminary study was undertaken to examine the
immunogenicity of these new cryopreserved allograft
valves and nonvalved patch tissue grafts as related to the
development of anti-HLA antibodies. In addition, we com-
pared this new tissue with more traditional cryopreserved
allografts in terms of both functional results and rate of
calcification.
Patients and Methods
Patients
We prospectively enrolled 14 patients who received decellularized
cryopreserved allograft material (CryoValve SG; CryoLife, Inc,
Kennesaw, Ga) for reconstruction of congenital cardiac defects.
Ages of the patients ranged from 22 days to 21 years (mean  SD
8.5  7.9 years). Diagnoses included truncus arteriosus in 2
patients, tetralogy of Fallot in 3 patients, aortic stenosis with
pulmonary valve replacement for concomitant Ross procedure in 3
patients, pulmonary stenosis and insufficiency in 1 patient, supra-
valvular pulmonary stenosis in 2 patients, supravalvular aortic
stenosis in 1 patient, pulmonary artery aneurysm with pulmonary
valve insufficiency in 1 patient, and pulmonary atresia with intact
ventricular septum in 1 patient. The procedures included insertion
of a valved pulmonary allograft in 8 cases, pulmonary artery
monocusp insertion in the right ventricular outflow tract in 2 cases,
supravalvular pulmonary patch angioplasty in 3 cases, and allo-
graft patch aortoplasty in 1 case. The types of allografts inserted
included valved pulmonic allografts in 8 cases, pulmonary artery
patch (nonvalved) allografts in 4 cases, and pulmonary artery
monocusp patch allografts in 2 cases. Seven of the 14 patients had
undergone previous cardiac surgery, all without allograft implan-
tation.
Historical control subjects were used for comparison and con-
sisted of 20 patients unselected from previous studies who had
undergone implantation of standard cryopreserved allograft mate-
rial with identical techniques and methods of HLA testing, includ-
ing both class I and class II antibodies.10,11 This standard group
underwent implantation of 8 valved allografts, 7 allograft patches,
and 5 monocusp pulmonary patches. Ages of patients ranged from
12 days to 7 years (mean  SD 1.7  2.2 years). Implantation
techniques, study methods, and testing were identical for both
decellularized and standard allograft groups, and no attempt was
made to match ABO blood types in either group.
Allografts
All allografts in this study were obtained from CryoLife, Inc.
Standard cryopreserved allograft material was considered to be
allograft material that was harvested and cryopreserved according
to previously published methods.12,13 Decellularized cryopre-
served allograft material (SynerGraft; CryoLife, Inc) is prepared
by harvesting techniques similar to those used for standard allo-
graft material but undergoes a decellularization process that first
involves cell lysis in hypotonic sterile water solution. After that,
the allograft tissue is equilibrated in buffer and is treated by
enzymatic digestion of nucleic acids with a combined solution of
ribonuclease and deoxyribonuclease. The allograft tissue then un-
dergoes a multiday washout in isotonic neutral buffer to further
reduce cellular staining when evaluated with hematoxylin and
eosin staining of cryosectioned tissue.4 The processed decellular-
ized valves are then cryopreserved according to a controlled rate
freezing protocol.14 The resulting decellularized cryopreserved
allografts have been shown to have approximately a 99% reduction
in staining of endothelial and interstitial cellular elements, as well
as marked reduction in staining for class I and class II histocom-
patibility antigens.5
Study Methods
The study protocol was approved by the institutional review board
at Primary Children’s Medical Center as well as the University of
Utah Medical Center. Informed consent was obtained from the
parents or guardian of each patient before entrance into the study.
Blood was obtained for HLA panel-reactive antibody (PRA)
screens and specificity determination at the following times: im-
mediately before the operation and approximately 1, 3, and 12
months after implantation of the allograft material. As part of the
protocol, all patients received only blood products that had under-
gone both irradiation and leukocyte filtering to remove allogeneic
white blood cells that could sensitize the patients.15 All blood
products were irradiated with cesium 137 at 30 Gy and were
filtered with the use of Purecell leukocyte reduction filters (Pall
Biomedical Products Co, East Hills, NY). Children with identified
immunologic deficiencies such as DiGeorge syndrome were ex-
cluded from the study.
HLA-A, HLA-B, and HLA-C (class I) and HLA-DR/DQ (class
II) antibodies were determined by a sensitive flow cytometry
procedure.16 This technique uses affinity-purified, soluble class I
and class II antigens from 30 different cell lines that are coupled
individually to latex beads and then pooled together to create a
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panel that represents the majority of serologically recognized HLA
class I and class II alloantigens (Flow-PRA I and II Beads; One
Lambda, Canoga Park, Calif). The beads were incubated with 0.02
mL of patient serum and then washed washing and stained with
saturating fluorescein-conjugated goat antihuman immunoglobulin
G. After analysis on a Becton Dickinson FACScan flow cytometer
(BD Immunocytometry Systems, San Jose, Calif), the percentage
of fluorescent positive beads, indicative of the percentage of PRA,
was calculated.
Patients with valved allografts in both groups underwent echo-
cardiographic follow-up consisting of standard surface 2-dimen-
sional and Doppler echocardiography. Allograft stenosis was eval-
uated with standard Doppler techniques. The peak velocity across
the valved conduits was obtained with pulsed or continuous-wave
Doppler evaluation, and the gradient was determined with the
modified Bernoulli equation. Pulmonary valve regurgitation was
graded echocardiographically according to a method described
previously by us that has been validated and compared with
traditionally used angiographic measures.17 According to this
method, the ratio of the width of the pulmonary regurgitation color
jet to the diameter of the valve annulus in early diastole is used as
semiquantitative index of severity. A color jet to annulus ratio less
than 0.4 is classified as mild (1), a ratio of at least 0.4 but less
than 0.7 is classified as moderate (2), and a ratio of at least 0.7
is classified as severe (3).
Statistical Analysis
Comparisons between continuous data were made with unpaired t
test or analysis of variance and Scheffe´ post hoc analysis. All data
were expressed as mean  SD.
Results
Results are shown in Table 1. Both class I and class II HLA
antibodies were elevated slightly from baseline values in
patients receiving decellularized grafts at 1, 3, and 12
months, although these differences were not significant.
However, all values beyond baseline preoperative time
point for both class I and class II HLA antibodies were
significantly less in decellularized allografts than their cor-
responding values at the same time period for standard
allografts. Overall, 9 of the 14 patients exhibited no humoral
response, as defined as an elevation of PRA greater than
10% for either class I or class II antibodies at any time
period after the operation. Two other patients exhibited
elevation of PRA greater than 10% for both class I and class
II antibodies at 1 month, with 1 patient showing resolution
of the PRA to less than 10% for class II antibodies by 1 year
after the operation. Three additional patients showed eleva-
tion of PRA greater than 10% for just class II antibodies by
3 months after the operation, but by 1 year only 2 of these
patients still had a PRA level greater than 10% for class II
antibodies. Results for both class I and class II HLA anti-
bodies in the standard allograft group are shown in Table 1
and have been previously reported.10,11
Echocardiographic evaluation occurred at 8  2 months
after implantation in the 8 patients receiving decellularized
valved allografts and showed an average peak gradient of 13
 15 mm Hg, compared with an average peak gradient of
24  18 mm Hg measured 12  6 months after the oper-
ation in the 8 patients receiving standard cryopreserved
valved allografts (P .11). Evaluation for pulmonary valve
insufficiency in the patients receiving decellularized valved
allografts showed 5 patients with trivial or no pulmonary
valve regurgitation and 3 with moderate pulmonary valve
regurgitation. The standard cryopreserved valved allografts
demonstrated trivial or no pulmonary valve regurgitation in
3 patients, mild regurgitation in 3, moderate regurgitation in
1, and severe regurgitation in 1. One decellularized valved
allograft was explanted at 4 months concomitantly with
resection of an aneurysm of an untreated autologous peri-
cardial outflow patch used to “hood” the valved allograft.
Pathologic examination of this explant revealed cellular
ingrowth into the media of the graft (Figure 1), but the type
of cell could not be identified. Special stains were also done
to identify endothelial cells, but there was no definitive
evidence of endothelial cells on the luminal surface of the
explanted graft at 4 months. One patient (n  1/14, 7.1%)
exhibited calcification of a decellularized monocusp patch
within 1 year after the operation, as opposed to 1 patient (n
 1/20, 5%) with calcification of a standard valved allograft
within 1 year after the operation.
TABLE 1. Class I and class II alloantibody measurements in 14 patients after implantation of decellularized cryopreserved
allografts and 20 patients after implantation of standard cyropreserved allografts
Time since allograft
implantation
PRA (%, SD)
Decellularized allografts (n  14) Standard allografts (n  20)
Class I Class II Class I Class II
Before operation 0.3% 1% 0% 0% 5% 11% 0.3% 1%
33 14 d 5% 14%* 7% 15%* 57% 38% 35% 36%
3.3 0.7 mo 12% 30%* 14% 19%* 81% 9% 59% 33%
12 4 mo 8% 16%* 6% 10%* 73% 38% 38% 24%
*P  .05 versus standard allograft.
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Discussion
Cryopreserved allograft material is widely used in the de-
finitive repair and palliation of a variety of congenital car-
diac defects and has included valved allografts, monocusp
pulmonary valve patches, and nonvalved allograft patch
material. Standard cryopreserved allograft material demon-
strates preservation of endothelial and valve architecture
and viability.18 This viability may not be a positive at-
tribute, as initially thought, if it contributes to immunoge-
nicity and elicits a more vigorous immunologic reaction
from the recipient, especially if the heightened immune
response contributes to accelerated degeneration of allograft
valves. Previous studies in human subjects have demon-
strated formation of both class I and class II anti-HLA
antibodies in patients after allograft implantation with ho-
movital antibiotic-preserved allografts, as well as in patients
receiving standard commercially available cryopreserved
valved allografts.2,3,19-22 An immunologically neutral graft
has therefore been considered desirable, leading to the de-
velopment of a new cryopreserved allograft preparation
(CryoValve) that has been decellularized to avoid introduc-
tion of immunogenic cells into the recipient. This process is
claimed to leave the valve biologic matrix and structure
intact.4 When implanted in an animal model, the decellu-
larized valves are repopulated with fibroblasts and endothe-
lial cells of the recipient; the result more closely approxi-
mates a normal valve as well as being immunologically
neutral.4 Although our single explanted valve demonstrated
cellular ingrowth into the media of the graft, we were unable
to demonstrate definitive endothelial cell ingrowth (Figure
1) such as has been reported for animal studies.4 There has
been only one previous group reporting the use of these
decellularized allografts in human subjects, and their expe-
rience involved primarily adult patients.5,6 Similar to our
current study, they demonstrated that more than 90% of
patients without preoperative HLA antibodies continued to
have class I antibody levels less than 10% at 1 and 3 months
after the operation.6
This study demonstrated in a prospective manner that
these new decellularized allografts elicit a significantly re-
duced immune response to both class I (anti–HLA-A, anti–
HLA-B, and anti–HLA-C) and class II (anti–HLA-HLA
DR/DQ) alloantigens. Why a few patients respond immu-
nologically (PRA 10%), even in a transient fashion, while
most do not, cannot be yet be determined. The alloantibody
elicited in these grafts toward HLA-DR antigens is intrigu-
ing and may suggest some residual cells, notably highly
immunogenic, HLA class II–expressing dendritic cells that
may be more resistant to the decellularization process.
Although it has not been definitely proved, we and others
have speculated that the vigorous immune response mea-
sured by an elevated PRA may have significant negative
effects on allograft function and longevity.2,3,7,10,11 The
advantages of reduced immunogenicity are thus 2-fold.
First, an absent or at least reduced immunologic response
will allow investigators to better sort out the role that
immunology plays in allograft failure in children. Although
immunologic factors are likely to play a role in allograft
failure, they are intertwined with other factors associated
with graft failure, such as patient age, graft size, donor age,
Figure 1. Photomicrograph of decellularized cryopreserved pulmonary allograft explanted 4 months after opera-
tion. There is evidence of cellular ingrowth into media of graft, but no apparent cell staining of endothelial cells
on luminal side of graft (bottom).
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and allograft type, making isolation of a single factor dif-
ficult. Second, the presence of both class I and class II HLA
antibodies has significant implications if future heart or
other organ transplantation is needed. Some children receiv-
ing allograft valves or allograft patch material have signif-
icant heart disease or undergo palliative procedures antici-
pated to result in late transplantation. Examples of a group
of patients who are at risk for needing late transplantation
include those with single-ventricle physiology undergoing
palliative procedures with pulmonary artery reconstruction
with allograft patches and children with hypoplastic left
heart syndrome undergoing stage I palliation with a Nor-
wood procedure. The presence of donor-specific HLA class
I and class II antibodies has been shown to increase the risk
of acute or hyperacute cardiac allograft rejection and to
decrease graft survival.23,24 In addition, extremely high and
sustained PRA levels, as we3,10,11 and others19-22 have pre-
viously reported, may preclude or at least significantly delay
transplantation until a crossmatch-compatible donor can be
identified. Implantation of decellularized grafts, with the
lower level of PRA and even the absence of a response in
most cases, removes this impediment to transplantation.
There are several limitations of this study that make it
harder to determine whether decellularized allografts are
really an advance with respect to standard cryopreserved
allografts. First, this study is limited by a duration of fol-
low-up of less than 1 year and the relatively small number
of patients followed up during that time. Deterioration of
cryopreserved valved allografts is usually seen in the 3- to
5-year range for infants and the 5- to 10-year range for older
children.8,9 It will therefore take much larger numbers and
longer follow-up to document definitive improvement in
graft durability and function. Second, the comparison group
in this study was a historical group rather than a randomized
cohort. Although the methods used in the two study groups
were identical, the ages of the two groups were different.
There has been previous evidence of an increased immuno-
logic response in infants relative to adults, but we have not
seen any difference in PRA response in either class I or
class II antibodies in infants as compared with older chil-
dren in any of our previous studies.3,10,11,25,26 Use of a
randomized group of larger numbers of patients would
allow the most accurate comparison. In multiple other stud-
ies with standard cryopreserved allografts, however, we
have never been able to demonstrate the low HLA antibody
levels seen with the decellularized allografts in this
study.3,10,11,25,26 Third, histologic confirmation of tissue
ingrowth and the long-term biomechanical properties be-
yond animal studies are not known.4 The decellularized
allograft may possess unique biomechanical properties that
result in unknown extra risk of complications, such as
aneurysm or pseudoaneurysm formation, cusp dehiscence,
and possible other long-term effects of any differences in
compliance. Only a prospective, randomized trial with
longer follow-up will most accurately answer these ques-
tions. It may be even more difficult to establish superiority
or inferiority of nonvalved allograft patches, because there
is a low incidence of stenosis with standard nonvalved
allograft material. At present, benefits of decellularized non-
valved allograft patches can only been measured clinically
by the development of HLA antibodies and the possible
detrimental effect that this may have on a patient with
regard to allograft function and possible future transplanta-
tion. Longer-term experience with these decellularized
valves is necessary to balance the cost-benefit relative to
standard cryopreserved allografts and determine whether
the additional cost and potentially unknown long-term com-
plications are outweighed by the advantages of low immu-
nogenicity and possible improvements in durability.
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Discussion
Dr John E. Mayer, Jr (Boston, Mass). First let me congratu-
late Hawkins and colleagues on a clear presentation of important
work. The finding that decellularized homografts do not elicit the
same antibody response as cellular grafts is of significant interest,
particularly for patients who ultimately may require transplanta-
tion. I have found it interesting from a historical and scientific
standpoint how our pendulum has swung from the concept years
ago, when we were told that preserving the viability of cells on
homografts was critical to their long-term function, to the other
end of the spectrum. Now we’re being told that decellularization
will actually be a better process.
I have no specific comments about the antigenicity. And in
some ways I think that the findings are almost what one would
predict. But if one disregards those immunologic considerations, I
wondered about a few things.
First, Dr Hawkins, you have shown that the explanted graft of
homograft material was cellularized, but we don’t really know
what kind of cells they are. In particular, I wondered whether you
had any notions about what the cells on the luminal surface were
like. Have you done any studies on whether they’re true endothelial
cells? One of the fundamental differences between human beings and
most experimental animals is that the ability to reendothelialize seems
to be much less, growing in a few millimeters from either end of the
anastomosis between the artificial material and the true native vessel.
I wondered if you had any information about that.
Second, on the basis of your clinical experience with this
material, could you comment on the effects of the decellularization
process on the structural and hemodynamic performance of the
implanted material?
Dr Hawkins. Actually, we did do some special stains in this
case. I hesitate to make too many conclusions on the basis of a
single patient, but that happens to be all that I have. We did do
stains for endothelial cells and could not find any when we looked
at multiple areas with multiple stains. There is no doubt that there
are cells present. I could conjecture that they’re probably fibro-
blasts. But are they fibroblasts that function? Not only do we need,
at least theoretically, a graft that has normal cells that have grown
into it, we need those normal cells to function to the point that they
participate in protein and collagen turnover. So we don’t really
know the answer to the question of whether these cells are func-
tional. My guess is that they’re probably fibroblasts, and at least in
this case they were not endothelialized at 4 months.
Your second question has to do with my clinical experience
with the hemodynamic function of these decellularized grafts. I
think that a conclusion from the data that I presented today would
be premature. There is no way to know at this point what the
hemodynamic data are of these valved allografts versus standard.
They appear to be equivalent. But are they biomechanically iden-
tical to the human valve? I don’t know. I think that’s the claim, but
I don’t think we really know yet. My own personal opinion is that
the tissue seems—and I stress that this is an anecdotal observa-
tion—to stretch more and to be a bit more elastic than standard
allograft material; however, I believe that the experimental data
from the company and animal data indicate that it’s biomechani-
cally the same.
Dr W. Steves Ring (Dallas, Tex). Do you have any data on
what might be an appropriate third control group? That would be
patients who undergo bypass surgery. Even though you’ve filtered
your blood, what’s the elevation in the flow PRA in that particular
group of patients where you don’t have a homograft?
Dr Hawkins. When we did our original studies back in 1996,
we did a control group of about 14 or 15 children who underwent a
variety of cardiac procedures that did not include implantation of a
homograft but did include bypass with Leukopore-filtered irradiated
blood. Their PRA at 1 month and 3 months was 0. We did not do the
12-month time point, because we considered that it was probably not
ethical to put them through yet another blood sampling for to check a
level that was 0 at 3 months. So we have done such a control group.
I did not include it in this report for the sake of time.
Dr Marshall L. Jacobs (Philadelphia, Pa). Earlier today Dr
Zahid Amin, in discussing acute homograft conduit failure, iden-
tified persistent postoperative fever as a marker or predictive factor
with an odds ratio of 9.1, or something that seemed rather com-
pelling. It’s a simple observation to make. Was there any differ-
ence in the incidence of persistent postoperative fevers in your
decellularized patient group as compared with your historical
control group?
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